Ultrasensitive point-of-care immunoassay for secreted glycoprotein detects Ebola infection earlier than PCR.

Autor:	Fontes CM; Department of Biomedical Engineering, Duke University, Durham, NC 27708, USA., Lipes BD; Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA., Liu J; Department of Biomedical Engineering, Duke University, Durham, NC 27708, USA., Agans KN; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.; Galveston National Laboratory, University of Texas Medical Branch at Galveston, Galveston, TX 77550, USA., Yan A; Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA., Shi P; Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA., Cruz DF; Department of Biomedical Engineering, Duke University, Durham, NC 27708, USA., Kelly G; Department of Biomedical Engineering, Duke University, Durham, NC 27708, USA., Luginbuhl KM; Department of Biomedical Engineering, Duke University, Durham, NC 27708, USA., Joh DY; Department of Biomedical Engineering, Duke University, Durham, NC 27708, USA., Foster SL; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.; Galveston National Laboratory, University of Texas Medical Branch at Galveston, Galveston, TX 77550, USA., Heggestad J; Department of Biomedical Engineering, Duke University, Durham, NC 27708, USA., Hucknall A; Department of Biomedical Engineering, Duke University, Durham, NC 27708, USA., Mikkelsen MH; Department of Electrical and Computer Engineering, Duke University, Durham, NC 27708, USA., Pieper CF; Departments of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC 27710, USA., Horstmeyer RW; Department of Biomedical Engineering, Duke University, Durham, NC 27708, USA., Geisbert TW; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.; Galveston National Laboratory, University of Texas Medical Branch at Galveston, Galveston, TX 77550, USA., Gunn MD; Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA. michael.gunn@duke.edu ashutosh.chilkoti@duke.edu., Chilkoti A; Department of Biomedical Engineering, Duke University, Durham, NC 27708, USA. michael.gunn@duke.edu ashutosh.chilkoti@duke.edu.
Jazyk:	angličtina
Zdroj:	Science translational medicine [Sci Transl Med] 2021 Apr 07; Vol. 13 (588).
DOI:	10.1126/scitranslmed.abd9696
Abstrakt:	Ebola virus (EBOV) hemorrhagic fever outbreaks have been challenging to deter due to the lack of health care infrastructure in disease-endemic countries and a corresponding inability to diagnose and contain the disease at an early stage. EBOV vaccines and therapies have improved disease outcomes, but the advent of an affordable, easily accessed, mass-produced rapid diagnostic test (RDT) that matches the performance of more resource-intensive polymerase chain reaction (PCR) assays would be invaluable in containing future outbreaks. Here, we developed and demonstrated the performance of a new ultrasensitive point-of-care immunoassay, the EBOV D4 assay, which targets the secreted glycoprotein of EBOV. The EBOV D4 assay is 1000-fold more sensitive than the U.S. Food and Drug Administration-approved RDTs and detected EBOV infection earlier than PCR in a standard nonhuman primate model. The EBOV D4 assay is suitable for low-resource settings and may facilitate earlier detection, containment, and treatment during outbreaks of the disease. (Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu